Eli Lilly Agrees to Acquire Ajax Therapeutics for Up to $2.3 Billion in Cash
Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3 billion in cash, including an upfront payment and potential milestone-based payments. The acquisition is expected to strengthen Lilly's position in the biopharmaceutical sector.
Tickers: $LLY
Topics: acquisition Ajax Therapeutics biopharmaceutical Eli Lilly